Imaging protocol assesses molecular mechanism in the treatment of deadly childhood cancer

ANSTO's unique capabilities and expertise in the production and application of radiotracers for imaging have been highlighted in a recent publication in the journal Theranostics.

In collaboration with researchers from the Children's Cancer Institute (CCI) in Sydney, imaging was pivotal in understanding the mechanism of a promising new treatment developed at CCI for the childhood cancer neuroblastoma.

Dr. Arvind Parmar, Dr. Giancarlo Pascali and Dr. Orazio Vittorio of CCI led the development of a new PET imaging protocol using small quantity of the radioactive form of copper chloride that measured in vivo neuroblastoma tumour response to the drug Dextran-Catechin in a pre-clinical laboratory model.

Catechin is a polyphenol found in green tea and other healthy foods and its conjugation with dextran, a naturally occurring polysaccharide, sustains the anti-cancer action of Catechin.

More information: Arvind Parmar et al. In vivo [64Cu]CuCl2 PET imaging reveals activity of Dextran-Catechin on tumor copper homeostasis, Theranostics (2018). DOI: 10.7150/thno.29840 

To read more please visit: https://medicalxpress.com/news/2018-12-imaging-protocol-molecular-mechanism-treatment.html

Source: Medical Express